Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy - 04/05/18
![](/templates/common/images/mail.png)
This work was funded in part by a 2016 Dixon Translational Innovation Award to B.S.B. through the Northwestern University Clinical and Translational Sciences Institute and Northwestern Memorial Foundation, and the Northwestern University Allergy Immunology Research Program as well as T32 grant AI083216 to M.C.D. and K23 grant AI100995 to A.M.S. from the National Institute of Allergy and Infectious Diseases. |
|
Disclosure of potential conflict of interest: M. C. Dispenza reports a grant from NMH Dixon Translational Award and travel support from the American Academy of Allergy, Asthma & Immunology. J. A. Pongracic reports board membership: Food Allergy Research and Education (FARE); payment for lectures including service on speakers bureaus from Aimmune Therapeutics; and travel/accommodations/meeting expenses unrelated to activities listed from DBV Technologies, FARE, and Aimmune Therapeutics. A. M. Singh reports grants from the national Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases. B. S. Bochner reports a grant from 2016 Dixon Translational Innovation Award through the Northwestern University Clinical and Translational Sciences Institute and Northwestern Memorial Foundation; board membership: Allakos, Inc; consultancy: TEVA and AstraZeneca; grants/grants pending: NIH; patents (planned, pending, or issued): Johns Hopkins University; and stock/stock options: Allakos, Inc. |
Vol 141 - N° 5
P. 1914 - mai 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?